v3.23.3
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Nov. 03, 2022
Oct. 08, 2021
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]                    
Revenues         $ 5,848,000 $ 4,457,000 $ 14,580,000 $ 14,208,000 $ 28,674,000 $ 24,100,000
Other Operating Income                   500,000
Loss Contingency, Receivable   $ 6,200,000             $ 6,200,000  
Legal settlements receivable percentage 50.00% 50.00%     50.00%   50.00%   50.00%  
[custom:StockIssuedDuringPeriodSharesInvestmentInEquitySecurities] 6,280,396 6,446,946                
Equity Method Investment, Additional Information             3,377,346      
Biofrontera Pharma GmbH [Member]                    
Related Party Transaction [Line Items]                    
Interest Income, Operating               100,000    
Biofrontera AG [Member]                    
Related Party Transaction [Line Items]                    
Other Receivables $ 3,700,000 $ 6,100,000     $ 3,700,000   $ 3,700,000   $ 6,100,000  
Loss Contingency, Receivable $ 3,700,000 6,400,000     $ 3,700,000   $ 3,700,000   6,400,000 11,300,000
Legal settlements receivable percentage 50.00%       50.00%   50.00%      
Interest Income, Operating                 100,000 0.0
License and Supply Agreement [Member] | Biofrontera Pharma GmbH [Member]                    
Related Party Transaction [Line Items]                    
Cost of Revenue         $ 10,400,000 6,200,000 $ 13,700,000 11,500,000 16,600,000 9,400,000
Accounts Payable $ 4,700,000 1,300,000     4,700,000   4,700,000   1,300,000 300,000
License and Supply Agreement [Member] | Fifty Percent of Anticipated Net Price [Member]                    
Related Party Transaction [Line Items]                    
Revenues       $ 30,000,000            
License and Supply Agreement [Member] | Forty Percent of Anticipated Net Price [Member] | Minimum [Member]                    
Related Party Transaction [Line Items]                    
Revenues       30,000,000            
License and Supply Agreement [Member] | Forty Percent of Anticipated Net Price [Member] | Maximum [Member]                    
Related Party Transaction [Line Items]                    
Revenues       50,000,000            
License and Supply Agreement [Member] | Thirty Percent of Anticipated Net Price [Member]                    
Related Party Transaction [Line Items]                    
Revenues       $ 50,000,000            
Service Agreements [Member]                    
Related Party Transaction [Line Items]                    
Accounts Receivable, after Allowance for Credit Loss   6,500,000             6,500,000  
Other Receivables   6,400,000             6,400,000  
Service Agreements [Member] | Biofrontera AG [Member]                    
Related Party Transaction [Line Items]                    
Accounts Payable 200,000 200,000     200,000   200,000   200,000 200,000
Operating Costs and Expenses                 700,000 700,000
Other Operating Income           $ 300,000 100,000 $ 400,000    
Clinica Lamp Lease Agreement [Member] | Biofrontera Pharma GmbH [Member]                    
Related Party Transaction [Line Items]                    
Revenues                   100,000
Accounts Receivable, after Allowance for Credit Loss $ 500,000 100,000     $ 500,000   500,000   100,000 100,000
Cutanea Acquisition Agreement [Member] | Maruho Co, Ltd. [Member]                    
Related Party Transaction [Line Items]                    
Accounts Receivable, after Allowance for Credit Loss                   $ 100,000
Other Receivables   $ 0             0  
Share Purchase and Transfer Agreement [Member] | Maruho Co, Ltd. [Member]                    
Related Party Transaction [Line Items]                    
[custom:StockIssuedDuringPeriodValuesInvestmentInEquitySecurities]             $ 5,900,000   $ 10,500,000  
[custom:StockIssuedDuringPeriodSharesInvestmentInEquitySecurities]             6,280,396   6,466,949  
[custom:StockIssuedDuringPeriodSharesPurchase]     1,674,996              
[custom:TotalNumberOfSharesPurchased]     6,466,946              
[custom:StockIssuedDuringPeriodValuesPurchase]     $ 1,700,000